Company intelligence / Profile preview

Immunophotonics

Saint Louis, Missouri, United Statesimmunophotonics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Clinical-stage biotech developing IP-001 to reduce cancer recurrence through immune activation. Phase1b trials demonstrated safety and early anti-tumor activity. Currently in Phase1b/2a trials (NCT05688280, NCT03993678) and preparing Phase2/3 pivotal trial[1][3].

Therapeutic areas: Oncology
Modalities: Intratumoral immunotherapy
Industry: Biotech

Drug pipeline

1 asset

IP-001

Partnerships

partner_name:Johnson & Johnson Enterprise Innovation Inc., focus:Radiation-based tumor destruction combinations[1]partner_name:Cardiovascular and Interventional Radiological Society of Europe (CIRSE), focus:Phase2/3 trial design and implementation[3]

Beyond the preview

Go deeper on Immunophotonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunophotonics.

Explore the full profile